Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of MVC-COV1901 COVID-19 Vaccine
NCT04695652Phase 2Completed
- Sponsor
- Medigen Biotechnology
- Start
- Dec 2020
- Primary completion
- May 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of MVC-COV1901 in coronavirus disease 2019 (COVID-19), sponsored by Medigen Biotechnology. Started Dec 2020; status: completed.
02
Drugs
MVC-COV1901
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04695652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04695652.